FOXP3 and systemic lupus erythematosus: Rapamycin treatment alleviated SLE-like experimental lupus nephritis by the recovery of IL-2 production, which modulated the maintenance and expansion of CD4+FOXP3+ Tregs, in turn inhibiting activated effector T cells.